About Diabetic Therapeutic
The global diabetic therapeutic market is growing at a high pace owing to the increase in the prevalence of diabetes globally. The top countries with high prevalence of diabetes are China, India, the US, Brazil, Russia, Mexico, Indonesia, Egypt, Japan, and Bangladesh. It is estimated that more than 1.5 million deaths occur due to diabetes worldwide each year.
Technavio’s analysts forecast the global diabetic therapeutic market to grow at a CAGR of 7.55% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global diabetic therapeutic market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded drugs, generics, and biosimilars used for the treatment of diabetes. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period..
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Diabetic Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Eli Lilly
• Merck
• Novo Nordisk
• Sanofi
Other prominent vendors
• AbbVie
• Actelion Pharmaceuticals
• Adocia
• Aegerion Pharmaceuticals
• Akros Pharma
• Alnylam Pharmaceuticals
• Amarin
• Amgen
• Amicus Therapeutics
• Arbutus Biopharma
• Arena Pharmaceuticals
• Astellas Pharma
• Atheronova
• Aurobindo Pharma
• Baxalta
• Belrose Pharma
• BHV Pharma
• Biocon
• Biodel
• BioMarin
• Bionaturis
• Biosidus
• Biospherics
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Catabasis Pharmaceuticals
• Cerenis Therapeutics
• Chipscreen Biosciences
• Cipla
• CJ HealthCare
• CKD Bio
• Concord Biotech
• ConjuChem
• CureDM
• CymaBay Therapeutics
• Daewoong
• Daiichi Sankyo
• Dance Biopharm
• DiaMedica
• Diamyd Therapeutics
• Diasome Pharmaceuticals
• DiaVacs
• Dong-A ST
• Eisai
• Elcelyx Therapeutics
• Esperion Therapeutics
• Exsulin
• F. Hoffmann-La Roche
• Gan & Lee Pharmaceuticals
• Generex Biotechnology
• Genfit
• GlaxoSmithKline
• HanAll BioPharma
• Hanmi Pharmaceutical
• Hua Medicine
• Iltoo Pharma
• Intarcia Therapeutics
• InteKrin Therapeutics
• Intrexon
• Ionis Pharmaceuticals
• Islet Sciences
• ISU Abxis
• Janssen Pharmaceuticals
• Japan Tobacco
• JCR Pharmaceuticals
• JW Pharmaceuticals
• Kadmon Pharmaceuticals
• Kamada
• KinDex Pharmaceuticals
• Kissei
• Kotobuki
• Kowa Company
• Laboratoires SMB
• Lexicon Pharmaceuticals
• Ligand Pharmaceuticals
• Living Cell Technologies
• Livzon
• LIXTE Biotechnology
• Lupin
• MacroGenics
• Madrigal Pharmaceuticals
• MannKind Corporation
• MedImmune
• Melior Pharmaceuticals
• Merrion Pharmaceuticals
• Merz Pharmaceuticals
• Metabolic Solutions Development
• Mitsubishi Tanabe Pharma
• Mylan
• Neothetics
• Neuraltus Pharmaceuticals
• NGM Biopharmaceuticals
• Norgine
• Novartis
• NuSirt Biopharma
• Oramed
• Orexigen Therapeutics
• Osiris Therapeutics
• Peptron
• Perle Biosciences
• Pfizer
• PhaseBio Pharmaceuticals
• Poxel
• Protalix BioTherapeutics
• Raptor
• Recordati
• Regeneron Pharmaceuticals
• REGENX BioSciences
• REGiMMUNE
• Rhythm Pharmaceuticals
• Saniona
• Santaris Pharma
• Sanwa Kagaku Kenkyusho
• Serometrix
• Shionogi
• Shire
• Sigma-Tau
• Sirona Biochem
• Strongbridge Biopharma
• Sun Pharma
• Takeda Pharmaceuticals
• Teva
• Thera Technologies
• Theracos
• Toleranzia
• Tolerion
• Torrent Pharmaceuticals
• Transition Therapeutics
• UCB
• Utrecht Holdings
• VeroScience
• Vivus
• vTv Therapeutics
• XBiotech
• Xeris Pharmaceuticals
• XOMA
• Zafgen
• Zydus Cadila
Market driver
• Change in patient preference
• For a full, detailed list, view our report
Market challenge
• Complex storage conditions and distribution policies for insulin
• For a full, detailed list, view our report
Market trend
• Focus on oral insulin therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Disease overview: Diabetes
• Diagnosis of diabetes
• Complications associated with high blood glucose levels
PART 06: Pipeline portfolio
• Pipeline for new drug application (NDA) filings
• Pipeline for Phase III molecules
• Pipeline for Phase II molecules
• Pipeline for Phase I molecules
• Pipeline for pre-clinical stage molecules
• Pipeline for discovery stage molecules
PART 07: Market landscape
• Market overview
• Five forces analysis
PART 08: Overview of marketed products
• Synopsis of key diabetic drugs
• Marketed product profiles
PART 09: Market segmentation by type of disease
• Global type 1 diabetes market
• Global type 2 diabetes market
• Global gestational diabetes market
PART 10: Market segmentation by drug class
• Insulin therapies
• Non-insulin therapies
PART 11: Geographical segmentation
• Diabetic therapeutic market in Americas
• Diabetic therapeutic market in US
• Diabetic therapeutic market in EMEA
• Diabetic therapeutic market in Europe
• Diabetic therapeutic market in Germany
• Diabetic therapeutic market in UK
• Diabetic therapeutic market in France
• Diabetic therapeutic market in Italy
• Diabetic therapeutic market in Spain
• Diabetic therapeutic market in APAC
• Diabetic therapeutic market in China
• Diabetic therapeutic market in India
PART 12: Market drivers4
• Change in patient preference
• Focus on self-management of diabetes
• The strong potential of biologics
• Unmet medical needs and scope for DMDs
PART 13: Impact of drivers
PART 14: Market challenges
• Complex storage conditions and distribution policies for insulin
• Unpredictable outcomes on human due to lack of predictable animal models
• Gap in nation-level diabetes management plans
• Rising concerns in the scientific community
PART 15: Impact of drivers and challenges
PART 16: Market trends
• Focus on oral insulin therapies
• Growing technological integration fueling the market growth
• Focus on regenerative medicines
• Strong and diversified pipeline portfolio
PART 17: Vendor landscape8
• Competitive scenario
• Market analysis 2016
• Upcoming vendors for oral insulin therapies
• Oramed Pharmaceuticals
• Generex Biotechnology
• Other prominent vendors
PART 18: Key vendor analysis
• Novo Nordisk
• Sanofi
• Merck
• Eli Lilly
• AstraZeneca
PART 19: Appendix
• List of abbreviations
PART 20: Explore Technavio
?
?
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Types of diabetes
Exhibit 03: Diagnosis of diabetes
Exhibit 04: Market share of pipeline molecules
Exhibit 05: NDA filings: Global diabetic therapeutic market
Exhibit 06: Phase III pipeline portfolio: Global diabetic therapeutic market
Exhibit 07: Phase II pipeline portfolio: Global diabetic therapeutic market
Exhibit 08: Phase I pipeline portfolio: Global diabetic therapeutic market
Exhibit 09: Pre-clinical pipeline portfolio: Global diabetic therapeutic market
Exhibit 10: Pipeline portfolio for discovery stage molecules: Global diabetic therapeutic market
Exhibit 11: Market snapshot of global diabetic therapeutic market 2016-2021
Exhibit 12: Overview of global diabetic therapeutic market 2016-2021
Exhibit 13: Global diabetic therapeutic market 2016-2021 ($ billions)
Exhibit 14: Prospects of the global diabetic therapeutic market
Exhibit 15: Vendors' strategies and the un-addressed needs for global diabetic therapeutic market
Exhibit 16: Global diabetic therapeutic market snapshot: Developed and emerging markets 2016
Exhibit 17: Factors affecting the insulin therapies
Exhibit 18: Global diabetic therapeutic market: Present and outlook and its impact
Exhibit 19: Five forces analysis
Exhibit 20: Information on key marketed diabetic drugs
Exhibit 21: Product profiles of marketed products: Standard insulin therapies
Exhibit 22: Product profiles for marketed products: Non-insulin therapies - DPP-4 class
Exhibit 23: Product profiles for marketed products: Non-insulin therapies - GLP-1 class
Exhibit 24: Product profiles for marketed products: Non-insulin therapies - SGLT2s class
Exhibit 25: Segmentation of global diabetic therapeutic market by type of disease (2016)
Exhibit 26: Market overview of global type 1 diabetes market 2016-2021
Exhibit 27: Opportunity analysis of global type 1 diabetes market
Exhibit 28: Global type 1 diabetes market 2016-2021 ($ billions)
Exhibit 29: Market overview of global type 2 diabetes market 2016-2021
Exhibit 30: Opportunity analysis of global type 2 diabetes market
Exhibit 31: Global type 2 diabetes market 2016-2021 ($ billions)
Exhibit 32: Global gestational diabetes market 2016-2021 ($ billions)
Exhibit 33: Overview of global diabetic therapeutic market by drug class, 2016
Exhibit 34: Snapshot of global diabetic therapeutics market by geography
Exhibit 35: Global diabetes therapeutics market segmentation by region: Market growth lifecycle analysis 2016
Exhibit 36: Diabetic therapeutic market revenue by geography 2016-2021 ($ billions)
Exhibit 37: Overview of diabetic therapeutic market in Americas
Exhibit 38: Diabetic therapeutic market in Americas 2016-2021 ($ billions)
Exhibit 39: Overview of diabetic therapeutic market in US
Exhibit 40: Opportunity analysis: Diabetic therapeutic market in US
Exhibit 41: PESTLE analysis: Diabetic therapeutic market in US
Exhibit 42: Overview of diabetic therapeutic market in EMEA
Exhibit 43: Diabetic therapeutic market in EMEA 2016-2021 ($ billions)
Exhibit 44: Share of diabetic therapeutic market in EMEA 2016
Exhibit 45: Overview of diabetic therapeutic market in Europe
Exhibit 46: Diabetic therapeutic market: Regional outlook of Europe, 2016 and 2021
Exhibit 47: Opportunity analysis: Diabetic therapeutic market in Europe
Exhibit 48: PESTLE analysis: Diabetic therapeutic market in Europe
Exhibit 49: Overview of diabetic therapeutic market in Germany
Exhibit 50: Opportunity analysis: Diabetic therapeutic market in Germany
Exhibit 51: Overview of diabetic therapeutic market in UK
Exhibit 52: Opportunity analysis: Diabetic therapeutic market in UK
Exhibit 53: Overview of diabetic therapeutic market in France
Exhibit 54: Opportunity analysis: Diabetic therapeutic market in France
Exhibit 55: Overview of diabetic therapeutic market in Italy
Exhibit 56: Opportunity analysis: Diabetic therapeutic market in Italy
Exhibit 57: Overview of diabetic therapeutic market in Spain
Exhibit 58: Opportunity analysis: Diabetic therapeutic market in Spain
Exhibit 59: Overview of diabetic therapeutic market in APAC
Exhibit 60: Diabetic therapeutic market: Regional outlook, APAC, 2016 and 2021
Exhibit 61: Diabetic therapeutic market in APAC 2016-2021 ($ billions)
Exhibit 62: Overview of diabetic therapeutic market in China
Exhibit 63: Opportunity analysis: Diabetic therapeutic market in China
Exhibit 64: Pest analysis: Diabetic therapeutic market in China
Exhibit 65: Overview of diabetic therapeutic market in India
Exhibit 66: Opportunity analysis: Diabetic therapeutic market in India
Exhibit 67: PESTLE analysis: Diabetic therapeutic market in India
Exhibit 68: Impact of drivers and challenges in global diabetes therapeutic market
Exhibit 69: Impact of drivers
Exhibit 70: Impact of drivers and challenges
Exhibit 71: Impact of trends in global diabetic therapeutic market
Exhibit 72: Oral insulin pipeline portfolio
Exhibit 73: Key technological integrations
Exhibit 74: Regenerative medicines under development for the treatment of diabetes
Exhibit 75: Competitive structure analysis of global diabetic therapeutic market 2016
Exhibit 76: Top-selling diabetic therapeutics based on sales 2015 ($ billions)
Exhibit 77: Geographical presence of key vendors
Exhibit 78: Competitive scenario: Global diabetic therapeutic market vendors 2016-2021
Exhibit 79: Oramed Pharmaceuticals: Pipeline products
Exhibit 80: Novo Nordisk: Key products in diabetes market
Exhibit 81: Novo Nordisk: Profile
Exhibit 82: Novo Nordisk: Strength analysis
Exhibit 83: Novo Nordisk: Strategy assessment
Exhibit 84: Novo Nordisk: Opportunity assessment
Exhibit 85: Sanofi: Key product offerings in diabetes market
Exhibit 86: Sanofi: Profile
Exhibit 87: Sanofi: Strength analysis
Exhibit 88: Sanofi: Strategy assessment
Exhibit 89: Sanofi: Opportunity assessment
Exhibit 90: Merck: Profile
Exhibit 91: Merck: Strength analysis
Exhibit 92: Merck: Strategy assessment
Exhibit 93: Merck: Opportunity assessment
Exhibit 94: Eli Lilly: Top-selling diabetic drugs in 2015
Exhibit 95: Eli Lilly: Profile
Exhibit 96: Eli Lilly: Strategy assessment
Exhibit 97: Eli Lilly: Opportunity assessment
Exhibit 98: AstraZeneca: Top-selling diabetes drugs in 2015
Exhibit 99: AstraZeneca: Profile9
Exhibit 100: AstraZeneca: Strength analysis
Exhibit 101: AstraZeneca: Strategy assessment
Exhibit 102: AstraZeneca: Opportunity assessment
